NVS Stock Summary and Trading Ideas (Novartis Ag | NYSE:NVS)

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Novartis Ag trades on the NYSE stock market under the symbol NVS.

As of September 8, 2026, NVS stock price declined to $137.70 with 8,815,084 million shares trading.

NVS has a beta of 0.02, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.

NVS has a market cap of $261.73 billion. This is considered a Mega Cap stock.

Last quarter Novartis Ag reported $14 billion in Revenue and $2.41 earnings per share. This beat revenue expectation by $284 million and exceeded earnings estimates by $.25.

In the last 3 years, NVS traded as high as $170.46 and as low as $92.19.

The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, PPH, AVDE.

NVS has underperformed the market in the last year with a price return of +10.9% while the SPY ETF gained +19.2%. NVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.2% and -13.3%, respectively, while the SPY returned +1.4% and 0.0%, respectively.

NVS support price is $157.57 and resistance is $162.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.